ImmunoPET and fluorescence imaging indicated that radiolabeled or fluorescence-labeled HER2 probes are promising for the management of ATCs, which may become helpful tools for image-guided tumor removal or identifying HER2-positive ATCs for HER2-targeted therapies. This evidence concerns the gene ERBB2 and Ehlers-Danlos syndrome, musculocontractural type.